AbD Serotec Significantly Improves Antibody Generation Process
(Thomson Reuters ONE) -
MorphoSys AG / AbD Serotec Significantly Improves Antibody Generation Process processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Automation and HuCAL PLATINUM Support Increase in Success Rates to 98%
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced that its
research and diagnostic antibody unit AbD Serotec has demonstrated significant
progress using the HuCAL-based technology platform to generate custom-made
monoclonal antibodies for research and diagnostic use. Over the course of the
last four years, AbD Serotec gradually improved success rates year-on-year
starting at 80% in 2006 to reach 98% in 2009. This was mainly achieved through a
high degree of automation in many aspects of the antibody generation process, by
optimizing protocols and finally by the implementation of HuCAL PLATINUM, the
latest and most powerful version of MorphoSys's antibody libraries.
"Thanks to the very effective technology and process development efforts at AbD
Serotec, we have managed to deliver antibodies in almost every customer project
we initiated in 2009. The success rates achieved by AbD Serotec in 2009 are
significantly higher than the average success rate usually seen in the industry
with animal-based methods, of around 75%,'' commented Dieter Feger, Head of AbD
Serotec. "The HuCAL technology is making ever-increasing inroads into the
diagnostics market as its intrinsic advantages are recognized."
About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies
for therapeutic, diagnostic and research applications. The Company's HuCAL
technology is one of the most powerful methods available for generating fully
human antibodies. By successfully applying this and other proprietary
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human health-care.
Through its alliances with some of the world's leading pharmaceutical companies,
MorphoSys has created a pipeline of more than 60 drug candidates. The Company is
expanding its drug pipeline by adding new partnered programs, and by building a
portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio,
the Company is focused on the areas of oncology and inflammation. Its most
advanced program MOR103, a first-in-class, fully human antibody against GM-CSF,
is currently tested in a Phase Ib/IIa trial in rheumatoid arthritis patients.
Via its business unit AbD Serotec, MorphoSys is expanding the reach of its
technologies in the diagnostics and research markets. MorphoSys is headquartered
in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol
"MOR". For further information, visit http://www.morphosys.com/
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®) and RapMAT(®) are registered
trademarks of MorphoSys AG
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
[HUG#1386638]
--- End of Message ---
MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany
WKN: 663200;ISIN: DE0006632003;Index:MIDCAP,Prime All Share,CDAX,HDAX,TecDAX,TECH All Share;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Press Release: http://hugin.info/130295/R/1386638/345238.pdf
Unternehmensinformation / Kurzprofil:
Datum: 23.02.2010 - 07:30 Uhr
Sprache: Deutsch
News-ID 12823
Anzahl Zeichen: 0
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 194 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"AbD Serotec Significantly Improves Antibody Generation Process"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
